|
Laxman Pai, Opalesque Asia: SR One Capital Management, which spun out of GlaxoSmithKline, has closed on more than $600 million, substantially exceeding its target of $500 million, for its second venture capital fund.
The trans-Atlantic biotech venture capital firm said in a press release that Fund II is the second fund since SR One spun out from GlaxoSmithKline (GSK) in 2020 to form a fully independent investment firm.
The diverse investor base of existing and new limited partners includes endowments, foundations, pharmaceutical companies, pension funds, sovereign wealth funds, and family offices, it said.
"We received an incredible response to the fund and are grateful to our limited partners for their continued support and confidence in our team," said Simeon George, MD, Co-Founder and Chief Executive Officer, of SR One.
"SR One's model is built upon active collaboration and our ability to roll up our sleeves and help build value through multiple inflection points. We seek to partner with entrepreneurs building elite biotechnology companies, and we look forward to the potential development of new medicines for patients that Fund II may help bring to the market," Simeon added.
San Francisco Bay Area-headquartered said that with Fund II, SR One will continue to invest in biotechnology companies that have the potential to address significant gaps in the current treatment landscape. SR One's investment strategy focuses on providing financial and di...................... To view our full article Click here
|
RSS
